INVESTOR AGREEMENTInvestor Agreement • May 6th, 2016 • TESARO, Inc. • Pharmaceutical preparations • Delaware
THIS INVESTOR AGREEMENT (this “Agreement”) is made as of March 18, 2016, by and among TESARO, Inc., a Delaware corporation (the “Company”), The Northern Trust Company in its capacity as custodian (the “FF Investor”) for the Future Fund Investment Company No.4 Pty Ltd (ACN 134 338 926) of Level 43, 120 Collins Street, Melbourne, Victoria 3000 (the “FF Beneficial Investor”), the FF Beneficial Investor, Ally Bridge LB Healthcare Master Fund Limited and ABG Innovation III-SO Limited (together with Ally Bridge LB Healthcare Master Fund Limited, “Ally Bridge”).
STOCK PURCHASE AGREEMENTStock Purchase Agreement • May 6th, 2016 • TESARO, Inc. • Pharmaceutical preparations • Delaware
THIS STOCK PURCHASE AGREEMENT (this “Agreement”), is made as of February 24, 2016, by and among TESARO, Inc., a Delaware corporation (the “Company”), the investors listed on Exhibit A attached to this Agreement (each a “Purchaser” and together the “Purchasers”) and Future Fund Investment Company No.4 Pty Ltd, a proprietary limited company organized under the laws of Australia (the “FF Beneficial Investor”).
AMENDMENT NO. 2 TO COLLABORATION AND EXCLUSIVE LICENSE AGREEMENTCollaboration and Exclusive License Agreement • May 6th, 2016 • TESARO, Inc. • Pharmaceutical preparations
This Amendment No. 2 to the Collaboration and Exclusive License Agreement (this “Amendment”) effective as of February 29, 2016 (the “Amendment Date”), is entered into is made by and between (i) AnaptysBio, Inc., a Delaware corporation, having a place of business at 10421 Pacific Center Court, Suite 200, San Diego, California 92121 (“AnaptysBio”), and (ii) TESARO, Inc., a Delaware corporation, having a place of business at 1000 Winter Street, Suite 3300, Waltham, Massachusetts 02541 (“TESARO US”) and TESARO Development, Ltd., a Bermuda corporation, having its principal office at Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda (together with TESARO US, “TESARO”).
Amendment No. 2 To SECOND Amended and Restated INVESTORS’ RIGHTS AgreementRights Agreement • May 6th, 2016 • TESARO, Inc. • Pharmaceutical preparations
The Second Amended and Restated Investors’ Rights Agreement (as amended, the “Agreement”), dated as of June 6, 2011, among TESARO, INC., a Delaware corporation (the “Company”), the investors listed on Schedule A thereto (the “Investors”), OPKO Health, Inc., a Delaware corporation, and the persons listed on Schedule B thereto (the “Founders”), as amended by Amendment No. 1, dated as of July 7, 2011, is hereby amended by this Amendment No. 2 (this “Amendment”) as of March 18, 2016 (“Amendment Effective Date”). Any capitalized term used herein, but not defined herein, shall have the meaning of such term set forth in the Agreement.
